Efficacy of baclofen in trigeminal neuralgia and some other painful conditions. A clinical trial.

Abstract

Baclofen (beta-4-chlorophenyl-gamma-aminobutyric acid) shows analgesic properties in rats and resembles carbamazepine and phenytoin in its effects on the spinal trigeminal nucleus of cats. We have, therefore, conducted a clinical trial in 25 subjects, 16 suffering from trigeminal neuralgia, and 9 patients were affected by different painful conditions such as postherpetic neuralgia, tabes dorsalis, postarachnoid radiculitis. 5 of the former groups were refractory to or unable to tolerate carbamazepine. Baclofen has significantly exhibited analgesic efficacy: all groups, as a whole, were improved by 68.61%. These results substantiate that baclofen is useful in the treatment of trigeminal neuralgia and other painful conditions.

• Authors: L Steardo, A Leo, E Marano
• Journal: European neurology (Eur Neurol) Vol. 23 Issue 1 Pg. 51-5 ( 1984) ISSN: 0014-3022 [Print] Switzerland
• PMID: 6201366 (Publication Type: Clinical Trial, Comparative Study, Journal Article)

Chemical References

• Substance P
• Carbamazepine
• Phenytoin
• Baclofen

Topics

• Adult
• Amputation Stumps
• Baclofen (therapeutic use)
• Carbamazepine (therapeutic use)
• Clinical Trials as Topic
• Female
• Humans
• Male
• Middle Aged
• Neuralgia (drug therapy)
• Phenytoin (therapeutic use)
• Radiculopathy (drug therapy)
• Substance P (analogs & derivatives)
• Tabes Dorsalis (drug therapy)
• Trigeminal Neuralgia (drug therapy)